Background: Alcohol withdrawal syndrome (AWS) is a serious complication of alcohol use disorder (AUD), often requiring inpatient care and treatment with benzodiazepines. However, the associated risks of benzodiazepines highlight the need for safer, effective alternatives.
Objective: This review evaluates recent clinical trials investigating adjunct and alternative pharmacologic treatments for AWS, including magnesium, intranasal oxytocin, dexmedetomidine, and calcium carbonate.
Methodology: Findings from four randomized clinical trials were summarized: a multicenter study on magnesium supplementation (Airagnes et al.), a placebo-controlled trial on intranasal oxytocin (Melby et al.), a comparison of dexmedetomidine vs. diazepam (Mendez et al.), and a calcium carbonate intervention trial (Schuster et al.). Each study assessed AWS severity using the Clinical Institute Withdrawal Assessment for alcohol, Revised (CIWA-Ar) scores and other relevant clinical outcomes.
Results: Magnesium supplementation showed no significant improvement in AWS symptoms or benzodiazepine use unless a deficiency was present. Oxytocin demonstrated a trend toward reduced symptom severity and medication use, particularly in high alcohol consumers. Dexmedetomidine was superior to diazepam in sedation quality and hemodynamic stability. Calcium carbonate significantly reduced withdrawal symptoms and alcohol craving.
Conclusion: While benzodiazepines remain the standard, alternative agents like dexmedetomidine, oxytocin, and calcium carbonate show promise in managing AWS. Larger and well-controlled studies are needed to validate their clinical utility.

Alcohol withdrawal syndrome., Alcohol use disorder, Benzodiazepines, Magnesium supplementation, Intranasal oxytocin, Dexmedetomidine, Calcium carbonate.

AUD represents a major global health burden, contributing to 5.9% of all deaths worldwide and affecting approximately 57% of the global population. Despite this, only a minority of patients receive specialized care. AWS develops in nearly half of individuals with AUD, particularly during hospitalization, and is most prevalent among individuals aged 17-65 years. AWS arises within 6-24 hours of alcohol cessation and, if untreated, can progress to life-threatening complications such as seizures, delirium tremens, or even death. Hospitalizations due to AWS have increased in recent years, underscoring its clinical and economic significance.[1-4] Magnesium, an essential intracellular cation, is often deficient in AUD patients due to malabsorption and increased excretion. Hypomagnesemia, common in 20-30% of AUD cases, may worsen during AWS and has been linked to more severe withdrawal symptoms, increased complications, and higher mortality. Magnesium’s role as an N-Methyl-D-Aspartate (NMDA) receptor antagonist suggests it might reduce neuronal excitotoxicity and potentially decrease benzodiazepine use. However, evidence on magnesium supplementation is inconsistent. While some advocate routine use, others find insufficient support for it unless a deficiency is documented. Importantly, past research often lacked clinically relevant outcome measures like the CIWA-Ar scale, limiting applicability to real-world AWS management.[5-8]

Alcohol use poses a major global health challenge, contributing to 5.9% of all deaths worldwide in 2012. AWS, which develops within 6-24 hours after abrupt cessation in heavy drinkers, is due to an imbalance in excitatory and inhibitory neurotransmitters. If untreated, AWS can lead to severe complications, including seizures, hallucinations, delirium tremens, or death, though symptoms typically resolve within 72 hours with proper management.[9-14] Benzodiazepines, especially when administered symptom-triggered via standardized protocols, are currently the treatment of choice. However, due to their risks, including respiratory depression and dependency, their use is limited to supervised inpatient settings. This underscores the need for safer alternatives.[15-18]

Oxytocin, known for its anxiolytic and prosocial properties, has emerged as a potential treatment for substance and alcohol use disorders. A pilot study showed oxytocin nasal spray reduced both withdrawal symptoms and benzodiazepine use in AWS. The current study aims to evaluate further the efficacy of oxytocin nasal spray in hospitalized patients undergoing alcohol detoxification, with the primary outcome being the total oxazepam dose required over a three-day detox period.[19,20] Alcohol consumption affects 57% of the global population and contributes to numerous health issues, including cirrhosis, cardiovascular disease, psychiatric disorders, and AWS. AWS, most common in individuals aged 17-65, can lead to severe complications such as intensive care unit (ICU) admission and increased mortality if untreated.[21]

The CIWA-Ar scale is widely used to assess AWS severity and guide benzodiazepine therapy. Ethanol alters the central nervous system by enhancing gamma-aminobutyric acid (GABA) activity and suppressing glutamate, creating a chemical imbalance during withdrawal. Ethanol affects multiple neurotransmitter systems, particularly GABA receptors, which play a key role in alcohol’s sedative effects and withdrawal symptoms.[22] Chronic alcohol use changes the function and expression of GABA receptors. Genetic studies link GABA receptor subunits, especially GABRA2, to alcohol dependence and relapse risk. GABA also influences the stress response, and ethanol enhances GABAergic transmission through corticotropin-releasing hormone type 1 (CRH1) receptors in the amygdala. These neurobiological and genetic insights highlight the central role of GABA in alcohol dependence and withdrawal.[23]

No new medications for alcohol dependence have been approved since 2004, highlighting the urgent need for novel treatments. Acamprosate, a commonly used anti-craving drug, supports abstinence after detoxification, though its exact mechanism is unclear. It is believed to counteract the hyperglutamatergic state during protracted withdrawal. Intriguingly, studies in animal models suggest that calcium may be the active component of acamprosate, as calcium salts alone have shown similar effects in reducing alcohol craving and relapse.[24] Recent preclinical studies indicate dose-dependent effects of calcium on alcohol-related behaviors and cognitive functions. Clinically, higher plasma calcium levels in acamprosate-treated patients have been associated with longer abstinence periods and delayed relapse. Additionally, negative correlations have been observed between plasma calcium levels and both alcohol craving and breath alcohol concentration.[25]

Historically, intravenous calcium (“calmonose” therapy) was used to reduce withdrawal symptoms and shorten treatment duration, but the approach was largely abandoned until recent findings reignited interest in calcium’s potential role in alcohol dependence. New data also link reduced calcium, vitamin D, and calcitonin levels in alcohol-dependent individuals to increased alcohol craving, supporting the hypothesis that calcium regulation may influence addiction-related behaviors.[26]

Comparison of intervention and control groups at follow-up:
In a study by Airagnes et al., Participants were recruited during hospitalization at six French centers: Corentin-Celton, Louis-Mourier, Georges Pompidou, Sainte-Anne, La Mutuelle Générale de l’Éducation Nationale (MGEN), and Emile Roux. Admissions occurred on a scheduled or post-emergency basis. Inclusion criteria: age 18-75, current AWS, CIWA-Ar >8, and social insurance. Exclusion: acute psychiatric disorder, other diagnostic and statistical manual of mental disorders, Fifth Edition (DSM-5) substance use disorder (except caffeine/tobacco), recent magnesium supplementation (≤3 months), non-AWS cognitive disorders, or creatinine clearance <30 mL/min. From 16th Nov. 2017 to 23rd Oct. 2020, 101 patients were randomized; 3 were excluded for invalid consent, while -98 were included (49 per group). Study lasted ≤15 days. A CIWA-Ar score difference of 3.03 ensured 80% power (α=0.05). The intervention group received nine tablets/day (three per meal) of 465 mg magnesium lactate dehydrate (47.4 mg/tablet; total 426.6 mg/day). If digestive issues arose, the dosage was reduced to four tablets/day (189.6 mg). The control group received placebo tablets (lactose monohydrate and cellulose). All received standard care per French guidelines.

Baseline data included demographics, body mass index (BMI), AUDIT, Charlson Index, and clinical history. CIWA-Ar was measured at baseline, 48h, 72h, day 7, and day 15. Benzodiazepine doses were converted to diazepam equivalents using World Health Organization Defined Daily Doses (WHO DDDs). Magnesium levels were measured at baseline, 72h, and day 7 (range 0.75–1.0 mmol/L). Adverse events and patient satisfaction (PSQ-18) were recorded. Of the 98 participants, 70 (71.4%) were men, with a mean age of 49.1 years (SD: 10.3). Seizure and delirium tremens histories were reported in 2 (2.1%) and 5 (5.2%) participants, respectively. Benzodiazepine use was common (94.8%), and most received thiamine (91.8%), pyridoxine (86.7%), and niacin (82.6%). The baseline CIWA-Ar score was 12.0 (SD: 3.7) overall, 12.9 (SD: 4.4) in the intervention group, and 11.2 (SD: 2.6) in controls. Mean baseline magnesium was 0.8 mmol/L (SD: 0.1) with no correlation to CIWA-Ar (ρ = 0.06, P = 0.56).

A total of 87 (88.8%) reached the primary endpoint; 59 (60.2%) completed follow-up. Among 39 (39.8%) who dropped out, 32 (32.7%) were discharged home, 5 (5.1%) transferred, 1 (1.0%) left against advice, and 1 (1.0%, control) was excluded for GI bleeding. CIWA-Ar score reductions over 3 days were similar: 10.1 (SD: 5.2) in the intervention vs. 9.2 (SD: 3.9) in controls (P = 0.34); no significant differences were seen across follow-up (P = 0.31) or in time to CIWA-Ar score 0 (P = 0.26). Benzodiazepine use was comparable over 3 days (116.4 mg vs. 115.0 mg; P = 0.92) and 15 days (395.1 mg vs. 388.4 mg; P = 0.98). Magnesium levels increased (0.01/day, P < 0.001) with no between-group difference (P = 0.21). Satisfaction scores were similar (4.2 in both; P = 0.87). No significant subgroup differences or severe withdrawal events were observed. Adverse events occurred in 8 (16.3%) in the intervention and 11 (22.4%) in controls (P = 0.44), mostly mild (diarrhea).[27]

Efficacy of intranasal oxytocin vs placebo during alcohol withdrawal:
In the study by Melby et al., a double-blind, randomized, placebo-controlled trial was conducted at the Blue Cross Lade Addiction Treatment Center in Trondheim, Norway, involving 40 patients undergoing alcohol withdrawal. Adults aged 18–65 with high alcohol intake (8–30 drinks/day for ≥2 weeks) and prior severe withdrawal episodes were included. Key exclusions were concurrent sedative use, other substance dependencies (except nicotine/caffeine), severe psychiatric/somatic illness, BMI <17 kg/m², recent pregnancy/lactation, and inability to understand Norwegian. Participants were randomized 1:1 using a web-based system to receive intranasal oxytocin (24 IU/dose) or placebo, administered twice daily over three days. All patients underwent baseline assessments, including physical exam, CIWA-Ar scoring, labs (including PEth), urine drug screening, and standardized questionnaires (HSCL-10, sleep diary, Timeline Follow-Back).

The primary outcome was cumulative oxazepam dose over three days. Secondary outcomes included CIWA-Ar scores, HSCL-10 scores, and sleep quality. Oxazepam dosing followed a symptom-triggered CIWA-Ar protocol; diazepam, if used, was converted to oxazepam equivalents. All patients received standard vitamin/mineral supplementation. Sample size (n = 40) was powered to detect a 10 mg group difference in oxazepam use (α < 0.05, power > 0.80). Between-group differences were analyzed using t-tests and chi-square tests. Analyses were conducted in SPSS v23, with blinding maintained until study completion.

From October 2016 to November 2017, 40 participants were enrolled, with 39 (97.5%) completing the 3-day intervention. One patient left early but had completed CIWA-Ar and oxazepam treatment; thus, their data were included in all analyses except the Hopkins symptom checklist-10 (HSCL-10) and sleep. Baseline demographic and clinical characteristics (Table 1) showed no significant differences between groups, including when stratified by alcohol intake (>16 vs. ≤16 units/day) or phosphatidylethanol (Peth) levels (>2 vs. ≤2 μmol/L). Five participants (three placebo, two oxytocin) received diazepam instead of oxazepam due to seizure risk or insufficient response.

There were no significant differences between groups in total oxazepam dose, mean CIWA-Ar scores, or any other outcomes. Seven participants in the oxytocin group and nine in the placebo group required no oxazepam. Oxazepam doses varied widely (0-510 mg), with no significant between-group difference, even after excluding high-dose outliers or those who received no oxazepam.

In subgroup analyses, participants with >16 units/day alcohol intake had significantly higher oxazepam doses (115.9 mg vs. 35.8 mg, P = 0.031) and CIWA-Ar scores (8.37 vs. 4.77, P = 0.004) than those with ≤16 units. Oxazepam use was numerically lower in the oxytocin group than in the placebo across both intake groups, but differences were not significant. Similar non-significant trends were seen in CIWA-Ar scores. Among those with PEth >2 μmol/L, oxazepam use and CIWA-Ar scores were similar between oxytocin and placebo groups. No drug-related adverse effects were reported, though mild discomfort from spray volume was noted in both groups.[28]

Comparative efficacy of dexmedetomidine (DEX) and diazepam (DZP) in alcohol withdrawal:
In a study by Mendez et al., a randomized clinical trial conducted in Mérida, Mexico (Nov 2017–Feb 2018), included 40 male patients (18-54 years) with moderate-to-severe AWS (CIWA-Ar ≥11) and traumatic brain injury (TBI) grade I or II. Exclusion criteria included co-dependence on illicit drugs, severe comorbidities, and drug hypersensitivity. Patients were randomized (n = 20 per group) to receive either diazepam (DZP, 5–20 mg IV, up to 120 mg over 72 h) or dexmedetomidine (DEX, 0.2–0.7 mcg/kg/min IV infusion over 72 h). Both groups received supportive care, including thiamine, folic acid, vitamins, analgesics, antiemetics, nutrition, and cardiac monitoring. CIWA-Ar scores were assessed at baseline, 12 h, and 24 h, and every 90 minutes until the score was <10 on two consecutive assessments.

Primary outcomes were CIWA-Ar scores, total DZP/DEX dosage, mean heart rate (HR), and systolic blood pressure (SBP) over 24 hours. Secondary outcomes included total treatment duration and days of hospitalization. Randomization was computer-generated using Epidat v4.2, and data were analyzed using SPSS v24.0, applying T-tests, Mann–Whitney U, and Chi-square tests. A p-value <0.05 was considered significant. All 40 male patients completed the study (n = 20 per group). Baseline characteristics were comparable. DEX showed significantly better sedation in TBI grade I/II cases (85% vs. 35%, P = 0.003). CIWA-Ar scores at 12 hours were significantly lower in the DEX group (7.6 ± 1.78) compared to DZP (10 ± 2.05, P = 0.001). At 24 hours, scores were comparable (2.0 ± 0.35 vs. 2.25 ± 0.55, P = 0.051).

DEX patients maintained greater hemodynamic stability during the first 24 hours. Mean HR at 24 h was significantly lower with DEX (67.10 ± 4.22 bpm) than with DZP (73.85 ± 8.39 bpm, P = 0.002). However, overall mean HR during treatment did not significantly differ (118.35 ± 3.96 bpm for DEX vs. 111.50 ± 12.37 bpm for DZP, P = 0.067). SBP was significantly lower in the DEX group (137.95 ± 5.62 mmHg) compared to DZP (143.85 ± 2.30 mmHg, P = 0.001). Fourteen DEX patients completed treatment in fewer days compared to the DZP group, which showed longer durations in most cases. No adverse effects were reported for either drug. DEX provided better short-term sedation, greater hemodynamic stability (HR and SBP), and reduced treatment duration compared to DZP in AWS patients, although routine use requires further investigation.[29]

Impact of calcium carbonate on withdrawal, craving, and biochemical markers:
In a study by Schuster et al., a single-blind, randomized, controlled, two-arm clinical trial was conducted in Mannheim, Germany, from December 2016 to September 2018. Fifty-five alcohol-dependent patients (ICD-10/DSM-IV criteria) were enrolled for 14 days of inpatient withdrawal treatment and randomized to receive either calcium carbonate (800 mg + 5 µg vitamin D; n = 26) or sodium bicarbonate (1,000 mg; n = 29) daily from day 1. Blinding was single due to differing tablet quantities between groups. Inclusion criteria included age 18–70 and confirmed alcohol dependence. Exclusion criteria encompassed dependence on other substances (except nicotine), medications affecting calcium metabolism, severe physical illness, pregnancy, recent use of anti-craving drugs, and psychiatric instability.

Psychometric assessments were conducted on days 1, 7, and 14 using the CIWA-Ar (withdrawal), OCDS (craving), ADS and ADS-HR (dependence severity), BDI (depression), and PSS (stress). Blood samples for calcium, sodium, and liver enzyme levels were collected on the same days. Diazepam was used as needed for withdrawal symptoms and adjusted for in the analysis. Statistical analyses were performed using t-tests, chi-square tests, and ANOVA (controlling for gender). A two-tailed P < 0.05 was considered statistically significant. All analyses followed the intention-to-treat principle and used SPSS v25.

All 55 participants completed day 1; 70.9% (n = 39) remained by day 7, and 49.1% (n = 27) completed day 14. Baseline characteristics did not differ significantly between groups. Plasma calcium levels remained within the normal range but increased significantly in the calcium carbonate group by day 7 (P = 0.006) and day 14 (P = 0.015), while remaining stable in the sodium group.

Withdrawal symptoms, assessed via CIWA-Ar, were significantly lower on day 7 in the calcium group (mean reduction; t (37) = −3.090, P = 0.004). ANCOVA adjusting for gender confirmed this difference (P < 0.05). No significant group difference was found on day 1. Craving, measured by the OCDS, was significantly lower in the calcium group by day 14 (sum score: t = −2.105, P = 0.044; obsessive subscale: t = −2.306, P = 0.028). ANCOVA showed no group differences at day 1 or 7, but a significant difference at day 14 (sum score P = 0.048; obsessive subscale P = 0.004).

No significant differences were observed in diazepam use between groups (mean 29.13 mg in calcium vs. 25.83 mg in sodium, P = 0.754). Linear regression showed no significant association between diazepam dose and CIWA-Ar scores in either group. Overall, calcium carbonate administration significantly improved withdrawal and craving symptoms over 14 days, supporting its potential role as an adjunct treatment in alcohol detoxification.[30]

Table 1: Key findings and limitations of recent randomized trials

AWS represents a significant clinical challenge in patients with AUD, given its potential for serious complications such as seizures, delirium tremens, and increased mortality. While benzodiazepines remain the cornerstone of AWS treatment, their associated risks, including sedation, respiratory depression, and dependency, underscore the need for safer, effective alternatives. Several recent trials have explored adjunct or alternative therapies, with mixed outcomes.[26]

In the multicenter randomized trial by Airagnes et al., magnesium supplementation did not significantly reduce CIWA-Ar scores or benzodiazepine use compared to placebo, despite a small but significant increase in serum magnesium levels. These findings suggest that routine magnesium supplementation in AWS may not be beneficial unless hypomagnesemia is clearly documented.[27]

Conversely, the study by Melby et al. found that intranasal oxytocin was well tolerated and associated with a reduction in withdrawal severity and benzodiazepine use, particularly in patients with higher baseline alcohol intake. Although between-group differences were not statistically significant, the trend supports oxytocin’s potential as an adjunct therapy. Its prosocial and anxiolytic properties may play a role in modulating withdrawal-related stress and cravings.[28]

Dexmedetomidine, as evaluated by Mendez et al., demonstrated superior sedation, hemodynamic stability, and shorter treatment duration compared to diazepam. Notably, CIWA-Ar scores were significantly lower at 12 hours post-intervention. Dexmedetomidine’s mechanism of action on α2-adrenergic receptors provides a non-GABAergic pathway to symptom control, making it a promising option, especially in settings requiring intensive monitoring.[29]

In the study by Schuster et al., calcium carbonate significantly reduced both withdrawal symptoms and alcohol craving. These findings, combined with prior research suggesting a link between calcium levels and relapse risk, support calcium’s role as a biologically plausible adjunctive therapy. Given its safety profile and affordability, further large-scale trials are warranted.[30]

Overall, while benzodiazepines remain first-line therapy, these studies highlight emerging pharmacologic strategies that may reduce withdrawal severity, craving, or benzodiazepine reliance in AWS management.

Effective management of Alcohol Withdrawal Syndrome is critical to preventing serious complications and improving long-term outcomes in individuals with AUD. While benzodiazepines are currently the standard of care, their limitations drive the need for safer adjuncts or alternatives.

Recent trials reveal promising yet varied results: magnesium supplementation showed no significant benefit without confirmed deficiency; oxytocin demonstrated favorable trends in reducing withdrawal and benzodiazepine use; dexmedetomidine offered superior sedation and hemodynamic control; and calcium carbonate effectively reduced withdrawal severity and craving.

Collectively, these findings underscore the potential of novel agents in enhancing AWS treatment. Future research should focus on larger, well-powered trials to confirm efficacy and guide evidence-based integration into clinical practice.

Not reported

No funding

Corresponding Author:
Samatha Ampeti, PhD
Independent Researcher
Department of Content, medtigo India Pvt Ltd, Pune, India
Email: ampetisamatha9@gmail.com

Co-Authors:
Mansi Srivastava, Sonam Shashikala BV, Raziya Begum Sheikh, Patel Nirali Kirankumar, Shubham Ravindra Sali
Independent Researcher
Department of Content, medtigo India Pvt Ltd, Pune, India

All authors contributed to the conceptualization, investigation, and data curation by acquiring and critically reviewing the selected articles. They were collectively involved in the writing – original draft preparation and writing – review & editing to refine the manuscript. Additionally, all authors participated in the supervision of the work, ensuring accuracy and completeness. The final manuscript was approved by all named authors for submission to the journal.

Not applicable

None

None

https://doi.org/10.63096/medtigo30612312

Mansi S, Samatha A, Sonam SBV, Raziya BS, Patel NK, Shubham RS. Emerging Pharmacologic Strategies in the Management of Alcohol Withdrawal Syndrome: A Comparative Review of Randomized Clinical Trials. medtigo J Pharmacol. 2025;2(3):e30612312. doi:10.63096/medtigo30612312 Crossref